CASE REPORT
Acquired thrombotic thrombocytopaenic purpura of an atypical, oligosymptomatic course in an adolescent girl – case report
 
More details
Hide details
1
Student at Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
 
2
Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
 
3
Department of Paediatric, Haematology, and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
 
 
Submission date: 2022-11-18
 
 
Final revision date: 2023-01-05
 
 
Acceptance date: 2023-01-05
 
 
Publication date: 2023-06-06
 
 
Corresponding author
Andrzej Badeński
Andrzej Badeński, Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
 
 
Pediatr Pol 2023;98(2):170-175
 
KEYWORDS
TOPICS
ABSTRACT
Acquired thrombotic thrombocytopaenic purpura (TTP) in children is a rare immune-mediated haematological disease (iTTP) in which active thrombus formation and multiorgan symptoms resulting from ischaemia of specific organs occurs. A 16-year-old girl was admitted to the hospital with symptoms of haemorrhagic diathesis. Physical examination showed numerous small petechiae all over her body. Laboratory tests revealed thrombocytopaenia, increased parameters of inflammation, lactate dehydrogenase activity, and total bilirubin. Decreased a disintegrin and metalloproteinase with thrombospondin motifs, member 13 (ADAMTS-13) activity, and the ADAMTS-13 inhibitor were detected. At first, the symptoms were not specific enough, therefore initially some difficulties establishing a proper diagnosis occurred. Finally, the patient was diagnosed with primary autoimmune thrombocytopaenia and then underwent an adequate therapy with fresh frozen plasma (plasmapheresis and multiple infusions) combined with corticosteroids, which induced a sustained remission of the disease. The authors aimed to raise the awareness of the iTTP, especially with limited characteristic features, as presented, and highlight the significance of differential diagnosis.
REFERENCES (16)
1.
Kucukyurt S, Eskazan AE. Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP): strategies to improve outcomes. J Blood Med 2020; 11: 319-326.
 
2.
Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. J Thromb Haemost 2017; 15: 1889-1900.
 
3.
Scully M, Hunt BJ, Benjamin S, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335.
 
4.
Górska-Kosicka M, Windyga J. Praktyczne aspekty diagnostyki i leczenia zakrzepowej plamicy małopłytkowej. Varia Medica 2017; 1: 24-30.
 
5.
De Bruijn S, Maes MB, de Waele L, Vanhoorelbeke K, Gadisseur A. First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost 2021; 00: 1-5.
 
6.
Coppo P. Immune TTP pathogenesis: the rising sun on HLA. Blood 2020; 135: 2335-2336.
 
7.
Scully M. TTP: an open and shut (closed) case. Blood 2020; 136: 265-266.
 
8.
Stanley M, Michalski JM. Thrombotic thrombocytopenic purpura. Treasure Island (FL): StatPearls Publishing 2021, PMID: 28613472.
 
9.
Żurowska A, Szczepańska M, Dębska-Ślizień A, et al. Postępowanie z chorym z podejrzeniem mikroangiopatii zakrzepowej. Stanowisko Zespołu Koordynującego ds. Leczenia Atypowego Zespołu Hemolityczno-Mocznicowego. Forum Nefrol 2019; 12: 187-201.
 
10.
Grenda R. Genetyczne i autoimmunologiczne mikroangiopatie zakrzepowe u dzieci – współczesna strategia diagnostyki i leczenia. Pediatr Pol 2016; 91: 295-300.
 
11.
Abou-Ismail MY, Arafah Y, Fu P, Cao S, Schmaier AH, Nayak L. Outcomes of immune thrombotic thrombocytopenic purpura (iTTP) with upfront cyclophosphamide vs. rituximab. Front Med 2020; 7: 588526.
 
12.
Gui RY, Huang QS, Cai X, et al. Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. Br J Haematol 2020; 191: 269-281.
 
13.
Carden MA, Gaddh M, Hoskote A, et al. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv 2020; 4: 477-481.
 
14.
Tersteeg C, Roodt J, van Rensburg WJ, et al. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood 2017: 129: 1030-1038.
 
15.
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380: 335-346.
 
16.
Dutt T, Shaw RJ, Stubbs M, et al. Real-world experience with caplacizumab in the management of acute TTP. Blood 2021; 137: 1731-1740.
 
Journals System - logo
Scroll to top